Zhuhai Rundu Pharmaceutical Co Ltd Class A Asset Resilience Ratio
Zhuhai Rundu Pharmaceutical Co Ltd Class A asset resilience ratio. Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Zhuhai Rundu Pharmaceutical Co Ltd Class to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Zhuhai Rundu Pharmaceutical Co Ltd Class A (2020–2025)
Asset resilience ratio of Zhuhai Rundu Pharmaceutical Co Ltd Class A from 2020 to 2025. This chart shows how Zhuhai Rundu Pharmaceutical Co Ltd Class A's Asset Resilience Ratio has changed over time. Read Zhuhai Rundu Pharmaceutical Co Ltd Class debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Zhuhai Rundu Pharmaceutical Co Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Zhuhai Rundu Pharmaceutical Co Ltd Class's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥33.70K | 0.0% |
| Total Liquid Assets | CN¥33.70K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Zhuhai Rundu Pharmaceutical Co Ltd Class A maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhuhai Rundu Pharmaceutical Co Ltd Class A Industry Peers by Asset Resilience Ratio
Compare Zhuhai Rundu Pharmaceutical Co Ltd Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Zhuhai Rundu Pharmaceutical Co Ltd Class A Asset Resilience Ratio by Year (2020–2025)
Zhuhai Rundu Pharmaceutical Co Ltd Class A asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Zhuhai Rundu Pharmaceutical Co Ltd Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | CN¥53.63K ≈ $7.85K |
CN¥2.03 Billion ≈ $296.85 Million |
0.00pp |
| 2024-12-31 | 0.00% | CN¥65.71K ≈ $9.62K |
CN¥2.19 Billion ≈ $321.00 Million |
+0.00pp |
| 2023-12-31 | 0.00% | CN¥52.23K ≈ $7.64K |
CN¥2.23 Billion ≈ $325.99 Million |
0.00pp |
| 2022-12-31 | 0.00% | CN¥61.78K ≈ $9.04K |
CN¥2.29 Billion ≈ $334.56 Million |
0.00pp |
| 2021-12-31 | 0.00% | CN¥86.77K ≈ $12.70K |
CN¥1.91 Billion ≈ $279.41 Million |
-2.90pp |
| 2020-12-31 | 2.91% | CN¥44.01 Million ≈ $6.44 Million |
CN¥1.51 Billion ≈ $221.51 Million |
-- |
About Zhuhai Rundu Pharmaceutical Co Ltd Class A
Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, APIs, and pharmaceutical intermediates in China and internationally. It offers FDF for cardiovascular, gastrointestinal, antibiotics, analgetic and antipyretics, anti-virus, endocrinology, and respiratory; and pellets for excipient, antiulcerative, diabetes … Read more